Abstract
The past 20 years have seen a proliferation of scientific data on the pathophysiology of asthma. Most of these data were generated in mice using tool reagents, gene-deficient or transgenic animals. In contrast, studies on disease pathogenesis in patients are scarce. Previously, a good novel antiasthma target for drug development was one that abrogated asthma in mice when it was knocked out, neutralized or induced asthma when it was overexpressed. This type of approach led to many drug candidates that worked in mice but unfortunately failed in patients, thereby demonstrating that the results of experiments in mice are not always predictive of clinical efficacy. Currently, there is active debate about the use of mouse models in drug discovery. In this review, we summarize the obstacles and challenges faced when using experimental mouse models of asthma in drug discovery. We propose that the initial selection of a novel drug target begins with defining the unmet medical need and specific patient population, followed by a thorough evaluation of available human data, and, only then, well-planned and executed mouse asthma experiments. Using this approach, we argue that mouse models lend support for the target when the models are tailored for the specific asthma patient population, and that targeted, reliable, and predictive mouse models can indeed improve and accelerate the drug discovery process.
References
1.
Williams K, Roman J: Studying human respiratory disease in animals - role of induced and naturally occurring models. J Pathol 2016;238:220-232.
2.
Shin YS, Takeda K, Gelfand EW: Understanding asthma using animal models. Allergy Asthma Immunol Res 2009;1:10-18.
3.
Taube C, Dakhama A, Gelfand EW: Insights into the pathogenesis of asthma utilizing murine models. Int Arch Allergy Immunol 2004;135:173-186.
4.
Sagar S, Akbarshahi H, Uller L: Translational value of animal models of asthma: challenges and promises. Eur J Pharmacol 2015;759:272-277.
5.
Catley MC, Coote J, Bari M, Tomlinson KL: Monoclonal antibodies for the treatment of asthma. Pharmacol Ther 2011;132:333-351.
6.
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators: Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-1207.
7.
Fahy JV: Type 2 inflammation in asthma - present in most, absent in many. Nat Rev Immunol 2015;15:57-65.
8.
Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM: Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res 2011;12:114.
9.
Pelaia G, Vatrella A, Maselli R: The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012;11:958-972.
10.
Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G: Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-2466.
11.
Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K: Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 2015;70:748-756.
12.
Holgate ST: Trials and tribulations in identifying new biologic treatments for asthma. Trends Immunol 2012;33:238-246.
13.
Prinz F, Schlange T, Asadullah K: Believe it or not: How much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011;10:712.
14.
Hahn C, Erb KJ: The preclinical testing strategy for the development of novel chemical entities for the treatment of asthma. Curr Drug Targets 2008;9:443-451.
15.
Holmes AM, Solari R, Holgate ST: Animal models of asthma: value, limitations and opportunities for alternative approaches. Drug Discov Today 2011;16:659-670.
16.
Wenzel S: Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012;42:650-658.
17.
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-373.
18.
Hyde DM, Miller L, Schelegle ES, Fanucchi M, Van Winkle LS, Tyler N, Avdalovic MV, Evans M, Kajekar R, Buckpitt AR: Asthma: a comparison of animal models using stereological methods. Eur Respir Rev 2006;15:122-135.
19.
Mestas J, Hughes CC: Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-2738.
20.
Kips JC, Anderson GP, Fredberg JJ, Herz U, Inman MD, Jordana M, Kemeny DM, Lotvall J, Pauwels RA, Plopper CG, Schmidt D, Sterk PJ, Van Oosterhout AJ, Vargaftig BB, Chung KF: Murine models of asthma. Eur Respir J 2003;22:374-382.
21.
Finkelman FD, Wills-Karp M: Usefulness and optimization of mouse models of allergic airway disease. J Allergy Clin Immunol 2008;121:603-606.
22.
Epstein MM: Do mouse models of allergic asthma mimic clinical disease? Int Arch Allergy Immunol 2004;133:84-100.
23.
Nials AT, Uddin S: Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech 2008;1:213-220.
24.
Kim HY, DeKruyff RH, Umetsu DT: The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol 2010;11:577-584.
25.
Herz U, Braun A, Ruckert R, Renz H: Various immunological phenotypes are associated with increased airway responsiveness. Clin Exp Allergy 1998;28:625-634.
26.
Hayashi T, Adachi Y, Hasegawa K, Morimoto M: Less sensitivity for late airway inflammation in males than females in BALB/c mice. Scand J Immunol 2003;57:562-567.
27.
Kumar RK, Herbert C, Foster PS: Mouse models of acute exacerbations of allergic asthma. Respirology 2016;21:842-849.
28.
Lynch SV, Boushey HA: The microbiome and development of allergic disease. Curr Opin Allergy Clin Immunol 2016;16:165-171.
29.
Grundström J, Saarne T, Kemi C, Gregory JA, Waden K, Pils MC, Adner M, Gafvelin G, van Hage M: Development of a mouse model for chronic cat allergen-induced asthma. Int Arch Allergy Immunol 2014;165:195-205.
30.
Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG: The effects of lebrikizumab in patients with mild asthma following whole-lung allergen challenge. Clin Exp Allergy 2014;44:38-46.
31.
O'Byrne PM, Inman MD, Parameswaran K: The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001;108:503-508.
32.
Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, FitzGerald JM, Boedigheimer M, Davis BE, Dias C, Gorski KS, Smith L, Bautista E, Comeau MR, Leigh R, Parnes JR: Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014;370:2102-2110.
33.
Baatjes AJ, Smith SG, Dua B, Watson R, Gauvreau GM, O'Byrne PM: Treatment with anti-OX40L or anti-TSLP does not alter the frequency of T regulatory cells in allergic asthmatics. Allergy 2015;70:1505-1508.
34.
Werner-Klein M, Goggel R, Westhof A, Erb KJ: Development and characterisation of a novel and rapid lung eosinophil influx model in the rat. Pulm Pharmacol Ther 2008;21:648-656.
35.
Duechs MJ, Hahn C, Benediktus E, Werner-Klein M, Braun A, Hoymann HG, Gantner F, Erb KJ: TLR agonist-mediated suppression of allergic responses is associated with increased innate inflammation in the airways. Pulm Pharmacol Ther 2011;24:203-214.
36.
Duechs MJ, Tilp C, Tomsic C, Gantner F, Erb KJ: Development of a novel severe triple allergen asthma model in mice which is resistant to dexamethasone and partially resistant to TLR7 and TLR9 agonist treatment. PLoS One 2014;9:e91223.
37.
Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, Glanville N, Choy KJ, Jourdan P, Burnet J, Tuthill TJ, Pedrick MS, Hurle MJ, Plumpton C, Sharp NA, Bussell JN, Swallow DM, Schwarze J, Guy B, Almond JW, Jeffery PK, Lloyd CM, Papi A, Killington RA, Rowlands DJ, Blair ED, Clarke NJ, Johnston SL: Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 2008;14:199-204.
38.
Clarke DL, Davis NH, Majithiya JB, Piper SC, Lewis A, Sleeman MA, Corkill DJ, May RD: Development of a mouse model mimicking key aspects of a viral asthma exacerbation. Clin Sci (Lond) 2014;126:567-580.
39.
Han J, Takeda K, Gelfand EW: The role of RSV infection in asthma initiation and progression: findings in a mouse model. Pulm Med 2011;2011:748038.
40.
Barends M, Van Oosten M, De Rond CG, Dormans JA, Osterhaus AD, Neijens HJ, Kimman TG: Timing of infection and prior immunization with respiratory syncytial virus (RSV) in RSV-enhanced allergic inflammation. J Infect Dis 2004;189:1866-1872.
41.
Aeffner F, Davis IC: Respiratory syncytial virus reverses airway hyperresponsiveness to methacholine in ovalbumin-sensitized mice. PLoS One 2012;7:e46660.
42.
Marsland BJ, Scanga CB, Kopf M, Le Gros G: Allergic airway inflammation is exacerbated during acute influenza infection and correlates with increased allergen presentation and recruitment of allergen-specific T-helper type 2 cells. Clin Exp Allergy 2004;34:1299-1306.
43.
Krishnamoorthy N, Khare A, Oriss TB, Raundhal M, Morse C, Yarlagadda M, Wenzel SE, Moore ML, Peebles RS Jr, Ray A, Ray P: Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat Med 2012;18:1525-1530.
44.
Tilp C, Bucher H, Haas H, Duechs MJ, Wex E, Erb KJ: Effects of conventional tobacco smoke and nicotine-free cigarette smoke on airway inflammation, airway remodeling and lung function in a triple allergen model of severe asthma. Clin Exp Allergy 2016;46:957-972.
45.
Wenzel SE: Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-725.
46.
Scaparrotta A, Di Pillo S, Attanasi M, Rapino D, Cingolani A, Consilvio NP, Verini M, Chiarelli F: Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multidiscip Respir Med 2012;7:13.
47.
Barrecheguren M, Esquinas C, Miravitlles M: The asthma-chronic obstructive pulmonary disease overlap syndrome (acos): opportunities and challenges. Curr Opin Pulm Med 2015;21:74-79.
48.
McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, Henry A, Irvin CG, Piganelli JD, Ray A, Kolls JK: Th17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008;181:4089-4097.
49.
Moerloose KB, Pauwels RA, Joos GF: Short-term cigarette smoke exposure enhances allergic airway inflammation in mice. Am J Respir Crit Care Med 2005;172:168-172.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
